Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1

Supplemental Digital Content is available in the text. Objective: Patients with psoriasis have impaired vascular health and increased cardiovascular disease (CVD). Platelets are key players in the pathogenesis of vascular dysfunction in cardiovascular disease and represent therapeutic targets in cardiovascular prevention. The object of this study was to define the platelet phenotype and effector cell properties on vascular health in psoriasis and evaluate whether aspirin modulates the platelet-induced phenotype. Approach and Results: Platelets from psoriasis patients (n=45) exhibited increased platelet activation (relative to age- and gender-matched controls, n=18), which correlated with psoriasis skin severity. Isolated platelets from psoriasis patients demonstrated a 2- to 3-fold (P<0.01) increased adhesion to human aortic endothelial cells and induced proinflammatory transcriptional changes, including upregulation of IL 8 (interleukin 8), IL1β, and Cox (cyclooxygenase)-2 Platelet RNA sequencing revealed an interferon signature and elevated expression of COX-1, which correlated with psoriasis disease severity (r=0.83, P=0.01). In a randomized trial of patients with psoriasis, 2 weeks of 81 mg low-dose aspirin, a COX-1 inhibitor, reduced serum thromboxane (Tx) B2 and reduced brachial vein endothelial proinflammatory transcript expression >70% compared with the no-treatment group (P<0.01). Improvement in brachial vein endothelial cell inflammation significantly correlated with change in serum TxB2 (r=0.48, P=0.02). Conclusions: In patients with psoriasis, platelets are activated and induce endothelial cell inflammation. Low-dose aspirin improved endothelial cell health in psoriasis via platelet COX-1 inhibition. These data demonstrate a previously unappreciated role of platelets in psoriasis and endothelial cell inflammation and suggests that aspirin may be effective in improving vascular health in patients with psoriasis. Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT03228017.

[1]  P. Dagur,et al.  Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque. , 2020, The Journal of investigative dermatology.

[2]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. , 2019, Circulation.

[3]  W. Koenig,et al.  Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. , 2019, The Journal of investigative dermatology.

[4]  E. Fisher,et al.  Inflammasome Signaling and Impaired Vascular Health in Psoriasis , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[5]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. , 2019, Journal of the American Academy of Dermatology.

[6]  Kairong Cui,et al.  Neutrophil Subsets, Platelets, and Vascular Disease in Psoriasis , 2019, JACC. Basic to translational science.

[7]  A. Roddick,et al.  Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis , 2019, JAMA.

[8]  J. Hochman,et al.  Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. , 2019, Atherosclerosis.

[9]  A. Armstrong,et al.  Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial , 2018, Circulation. Cardiovascular imaging.

[10]  A. Assinger,et al.  Measuring and interpreting platelet-leukocyte aggregates , 2018, Platelets.

[11]  A. Heguy,et al.  Platelet Transcriptome Profiling in HIV and ATP-Binding Cassette Subfamily C Member 4 (ABCC4) as a Mediator of Platelet Activity , 2018, JACC. Basic to translational science.

[12]  J. Freedman,et al.  Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis , 2018, Circulation research.

[13]  K. Uryu,et al.  Platelet-Derived MRP-14 Induces Monocyte Activation in Patients With Symptomatic Peripheral Artery Disease. , 2018, Journal of the American College of Cardiology.

[14]  James A. Underberg,et al.  The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis , 2017, Current Atherosclerosis Reports.

[15]  H. Valdez,et al.  Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. , 2017, The Journal of investigative dermatology.

[16]  E. Fisher,et al.  Hyperglycemia enhances arsenic-induced platelet and megakaryocyte activation , 2017, Journal of Translational Medicine.

[17]  J. Berger,et al.  Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1&bgr; Pathway in Systemic Lupus Erythematosus , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[19]  K. Ghoreschi Faculty Opinions recommendation of Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. , 2016 .

[20]  R. Wahab,et al.  Increased internalization of complement inhibitor CD59 may contribute to endothelial inflammation in obstructive sleep apnea , 2016, Science Translational Medicine.

[21]  I. Bechmann,et al.  Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Lesley M. Chapman,et al.  Emerging roles for platelets as immune and inflammatory cells. , 2014, Blood.

[23]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[24]  G. Jemec,et al.  Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. , 2013, Journal of the American Academy of Dermatology.

[25]  J. Berger,et al.  Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy: A Pilot Study , 2013, Journal of acquired immune deficiency syndromes.

[26]  D. Dikshit,et al.  Platelets and atherothrombosis: causes, targets and treatments for thrombosis. , 2013, Current medicinal chemistry.

[27]  S. Devaraj,et al.  Inflammation, Atherosclerosis, and Psoriasis , 2013, Clinical Reviews in Allergy & Immunology.

[28]  A. Schuster,et al.  Platelets in atherothrombosis--diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases. , 2012, Current vascular pharmacology.

[29]  Shaun P Jackson,et al.  The role of platelets in atherothrombosis. , 2011, Hematology. American Society of Hematology. Education Program.

[30]  P. Hundelshausen,et al.  Platelets in atherosclerosis , 2011, Thrombosis and Haemostasis.

[31]  Russ B Altman,et al.  Platelet aggregation pathway. , 2011, Pharmacogenetics and genomics.

[32]  J. Berger,et al.  Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data , 2011, Journal of Thrombosis and Thrombolysis.

[33]  V. Fuster,et al.  Aspirin: A Historical and Contemporary Therapeutic Overview , 2011, Circulation.

[34]  L. Truedsson,et al.  Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. , 2010, Blood.

[35]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[36]  R. Tamagawa‐Mineoka,et al.  Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. , 2010, Journal of the American Academy of Dermatology.

[37]  E. Smyth Thromboxane and the thromboxane receptor in cardiovascular disease , 2010, Clinical lipidology.

[38]  E. Grove,et al.  A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease , 2010, Thrombosis and Haemostasis.

[39]  P. Factor,et al.  Vascular Inflammation in Obesity and Sleep Apnea , 2010, Circulation.

[40]  G. Rousseau,et al.  Existence of a microRNA pathway in anucleate platelets , 2009, Nature Structural &Molecular Biology.

[41]  M. Abdallah,et al.  Serum interferon-gamma is a psoriasis severity and prognostic marker. , 2009, Cutis.

[42]  D. Gilroy,et al.  Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans1 , 2009, The Journal of Immunology.

[43]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[44]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[45]  L. Jennings Role of platelets in atherothrombosis. , 2009, The American journal of cardiology.

[46]  J. Carucci,et al.  Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1 , 2008, The Journal of Immunology.

[47]  Yihong Yao,et al.  Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.

[48]  F. Nestle,et al.  Immunopathogenesis of Psoriasis , 2007, Clinical reviews in allergy & immunology.

[49]  G. Borthwick,et al.  Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox‐ independent mechanism , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  S. Daniels,et al.  Recommendations for blood pressure measurement in human and experimental animals; part 1: blood pressure measurement in humans. , 2006, Hypertension.

[51]  O. Boyman,et al.  Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.

[52]  C. Weber Platelets and chemokines in atherosclerosis: partners in crime. , 2005, Circulation research.

[53]  G. Weissmann,et al.  Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. de Waal Malefyt,et al.  Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. , 1998, The Journal of investigative dermatology.

[55]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.

[56]  Daniel W. Jones,et al.  Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.

[57]  K. Ley,et al.  Role of platelets in the development of atherosclerosis. , 2004, Trends in cardiovascular medicine.